0353 GMT - Australia-listed drug and device makers may have to consider moving production due to potential tariffs by the incoming Trump administration, UBS analysts write in a note. They say that the likes of vaccine giant CSL, hearing-implant maker Cochlear, breath-tech provider ResMed and radiopharmaceutical developer Telix may have to consider the origin of various inputs and the location of production. Tariffs could motivate relocation of facilities to the U.S. but result in lower profitability for companies, they say. Protective-garment maker Ansell could benefit from tariffs on Chinese gloves, they add. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
November 06, 2024 22:53 ET (03:53 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。